RESEARCH TRIANGLE PARK – BioCryst and Aerie Pharmaceuticals both reported losses this week. Here are the details.
- BioCryst
DURHAM – BioCryst Pharmaceuticals Inc. (BCRX) on Thursday reported a loss of $74.2 million in its first quarter.
The Durham, North Carolina-based company said it had a loss of 40 cents per share.
The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The drugmaker posted revenue of $49.9 million in the period, also missing Street forecasts. Five analysts surveyed by Zacks expected $50.6 million.
BioCryst shares have declined 26% since the beginning of the year. The stock has decreased 7.5% in the last 12 months.
- Aerie
DURHAM – Aerie Pharmaceuticals Inc. (AERI) on Thursday reported a loss of $35.9 million in its first quarter.
The North Carolina, North Carolina-based company said it had a loss of 76 cents per share. Losses, adjusted for non-recurring costs, were 66 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 65 cents per share.
The drugmaker posted revenue of $29.8 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $30.2 million.
Aerie shares have climbed 10% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $7.72, a decrease of 54% in the last 12 months.
